Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LecTec

This article was originally published in The Tan Sheet

Executive Summary

TheraPatch marketer hopes to "find a strategic investor, partner or an acquirer which will enable us to once again satisfy the NASDAQ SmallCap listing requirements," firm says in Nov. 27 release announcing NASDAQ stock delisting due to failure to satisfy minimum bid price and stockholder equity standards. Firm's issue now trades on OTC Bulletin Board. In 1LecTec's third quarter 10-Q filing, firm says it expects to "continue to operate at a net loss and experience negative cash flow...for the foreseeable future." While it has sufficient cash to fund operations through year end, future activities "will require additional investments...of equity or debt either by outside investors or as part of a business combination transaction." Firm reported a net loss of $370,461 in Q3, compared to a $1.2 mil. loss in the year-ago period...

You may also be interested in...



LecTec

CEO Rodney Young, board member Donald Wegmiller resign from the firm in early August. LecTec co-founder and director Alan Hymes, MD, will serve as the firm's chairman and CEO until further notice. TheraPatch marketer is seeking a buyer, strategic investor or partner to boost its financials and satisfy NASDAQ listing requirements (1"The Tan Sheet" Dec. 9, 2002, In Brief)...

Medicare’s Antibiotic Boost: Six Qualify For Add-On Payment

CMS final rule for hospital payment in 2021 includes enhanced payment for six novel antibiotics – including one that is not yet approved by FDA. New policies to encourage antibiotic innovation are clearly having an impact in the context of Medicare payments.

Second-Guessing FDA? Sage Zulresso Denied Add-On Status In Medicare

Medicare’s doubts about trial design for Sage’s postpartum depression therapy suggests even ‘breakthrough’-designated products can struggle with the ‘substantial clinical improvement’ standard for NTAP status. Denial of enhanced payment for Zulresso ends a long winning streak by innovators.

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel